Table 5.
Estimated cumulative breast cancer–free survival (six-marker definition) a
| Intrinsic subtype | 2-year BCFS | 95% CI | 3-year BCFS | 95% CI | 5-year BCFS | 95% CI |
|---|---|---|---|---|---|---|
| Luminal A |
96.7% |
95.2% to 98.3% |
92.8% |
90.6% to 95.0% |
85.8% |
82.7% to 88.9% |
| Luminal B |
91.5% |
88.6% to 94.4% |
85.2% |
81.6% to 89.0% |
77.1% |
72.8% to 81.7% |
| Luminal HER2 |
89.2% |
82.5% to 96.6% |
81.0% |
72.4% to 90.5% |
77.1% |
68.8% to 72.4% |
| HER2-enriched |
72.4% |
62.5% to 83.8% |
63.9% |
53.5% to 76.3% |
58.3% |
47.6% to 71.5% |
| Basal-like |
80.8% |
74.3% to 87.9% |
72.2% |
64.9% to 80.4% |
68.1% |
60.5% to 76.7% |
| TNP nonbasal | 89.3% | 80.9% to 98.6% | 80.6% | 70.0% to 92.8% | 66.7% | 54.2% to 82.1% |
aBCFS, breast cancer–free survival; CI, confidence interval; HER2, human epidermal growth factor 2; TNP, triple-negative phenotype. All values are statistically significant.